PubMed · 10485381
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
M S de Bruin-Weller, E F Knol, C A Bruijnzeel-Koomen. 1999. Atopy patch testing--a diagnostic tool?. https://doi.org/10.1034/j.1398-9995.1999.00097.x
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
In the United Kingdom, laboratory animal allergy (LAA) has been recognized as an important occupational disease for nearly 25 years. However, introduction of health and safety legislation (e.g., the Control of Substances Hazardous to Health Regulations of 1988) and an increasing knowledge of the factors that contribute to the etiology of this disease have had surprisingly little impact on the prevalence and incidence of LAA over the last 10 to 20 yr. Studies of the relation between exposure to animal allergens and the development of LAA reveal that the risk of disease increases with increasing intensity of exposure. Current evidence suggests that animal allergens are very potent, and substantial decreases in allergen exposure are therefore necessary before a reduction in symptoms will be observed. In the United Kingdom, it is unlikely that an Occupational Exposure Limit will be set for animal allergens in the near future, partly because an adequately standardized assay for quantifying exposure is not yet available. Prevention of LAA in the future will probably be driven by the needs of the industry and will most likely rely on the adoption of guidelines describing " best practise" which incorporate sophisticated engineering methods of controlling exposure to animal allergens.
Atopic dermatitis (AD) is a common inflammatory disease involving the skin and often other organs and systems, mainly respiratory. A definitive general consensus on the AD pathogenesis has not yet been established, however several lines of evidence suggest that T-cells play a crucial role in priming AD early-stage lesions. Main topics involved in the disease pathogenesis have been reviewed, which considered the concept of local and systemic haemopoietic events as important contributors to allergic inflammation, a concept now achieving great acceptance. The recently recognised atopic nature of the skin inflammation in AD has raised increasing interest for treatment with allergen-specific immunotherapy. However, we only found eight studies using specific immunotherapy (SIT) in AD, two double-blind, placebo-controlled (DBPC) and six observational. One controlled and five observational reported favourable outcomes. The one unique study providing negative results was flawed by the ineffective oral route of extract administration. Despite being encouraging, the reported results do not allow definitive conclusions based on meta-analytic techniques because the amount and quality of information in the literature is not sufficient. The highly promising sub-lingual immunotherapy (SLIT) is discussed with its potential capability of controlling not only the skin lesion severity but also its capability of preventing the development of atopic dermatitis into asthma.
C3, designated as Per a 1.0103 according to WHO/IUIS nomenclature, encoding a novel American cockroach allergen of 395 aa (44.6 kDa), is the first complete cDNA clone with a translatable immunoreactive protein among the reported group 1 cockroach allergens. Its deduced amino acid sequence possesses a signal sequence, phosphorylation sites, mitochondrial energy transfer protein signatures, and four repeats each sharing striking similarity with the corresponding repeats of the other cockroach allergens. The latter similarity suggests that the group 1 cockroach allergens might have evolved from a primordial mitochondrial sequence by exon duplication.